Pergolide in late‐stage Parkinson disease
Identifieur interne : 000A80 ( Main/Corpus ); précédent : 000A79; suivant : 000A81Pergolide in late‐stage Parkinson disease
Auteurs : A. E. Lang ; N. Quinn ; S. Brincat ; C. D. Marsden ; ParkesSource :
- Annals of Neurology [ 0364-5134 ] ; 1982-09.
Abstract
Twenty‐six patients with late‐stage Parkinson disease were given 0.4 to 15 mg of pergolide mesylate daily in addition to, or as replacement for, levodopa or bromocriptine therapy. Despite treatment with individually determined optimum doses of levodopa, bromocriptine, and anticholinergics, they had shown response failure or fluctuating response. Forty percent (11 patients) were unable to tolerate pergolide. Nausea and vomiting, somnolence, and psychiatric disturbances were the most frequent side effects. Eleven of the remaining patients improved on pergolide, 2 were unchanged, and 2 were slightly worse. Among the patients who benefited, pergolide improved dose‐related response fluctuations more than non‐dose‐related fluctuations, with a reduction in number and duration of “off” periods and improvement in quality of sleep and early morning akinesia but little change in freezing episodes. Despite treatment failure in many cases, pergolide is at present the best available drug for specific latestage management problems.
Url:
DOI: 10.1002/ana.410120305
Links to Exploration step
ISTEX:BE242EEB7060360B7C6EE28770D3AE6CA125B544Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pergolide in late‐stage Parkinson disease</title><author><name sortKey="Lang, A E" sort="Lang, A E" uniqKey="Lang A" first="A. E." last="Lang">A. E. Lang</name><affiliation><mods:affiliation>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</mods:affiliation></affiliation><affiliation><mods:affiliation>Current Address: Division of Neurology, Toronto Western Hospital, 399 Bathurst St, Toronto, Ont, Canada</mods:affiliation></affiliation></author><author><name sortKey="Quinn, N" sort="Quinn, N" uniqKey="Quinn N" first="N." last="Quinn">N. Quinn</name><affiliation><mods:affiliation>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</mods:affiliation></affiliation></author><author><name sortKey="Brincat, S" sort="Brincat, S" uniqKey="Brincat S" first="S." last="Brincat">S. Brincat</name><affiliation><mods:affiliation>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</mods:affiliation></affiliation></author><author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name><affiliation><mods:affiliation>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</mods:affiliation></affiliation></author><author><name sortKey="Parkes" sort="Parkes" uniqKey="Parkes" last="Parkes">Parkes</name><affiliation><mods:affiliation>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BE242EEB7060360B7C6EE28770D3AE6CA125B544</idno><date when="1982" year="1982">1982</date><idno type="doi">10.1002/ana.410120305</idno><idno type="url">https://api.istex.fr/document/BE242EEB7060360B7C6EE28770D3AE6CA125B544/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000A80</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pergolide in late‐stage Parkinson disease</title><author><name sortKey="Lang, A E" sort="Lang, A E" uniqKey="Lang A" first="A. E." last="Lang">A. E. Lang</name><affiliation><mods:affiliation>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</mods:affiliation></affiliation><affiliation><mods:affiliation>Current Address: Division of Neurology, Toronto Western Hospital, 399 Bathurst St, Toronto, Ont, Canada</mods:affiliation></affiliation></author><author><name sortKey="Quinn, N" sort="Quinn, N" uniqKey="Quinn N" first="N." last="Quinn">N. Quinn</name><affiliation><mods:affiliation>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</mods:affiliation></affiliation></author><author><name sortKey="Brincat, S" sort="Brincat, S" uniqKey="Brincat S" first="S." last="Brincat">S. Brincat</name><affiliation><mods:affiliation>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</mods:affiliation></affiliation></author><author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name><affiliation><mods:affiliation>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</mods:affiliation></affiliation></author><author><name sortKey="Parkes" sort="Parkes" uniqKey="Parkes" last="Parkes">Parkes</name><affiliation><mods:affiliation>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1982-09">1982-09</date><biblScope unit="volume">12</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="243">243</biblScope><biblScope unit="page" to="247">247</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">BE242EEB7060360B7C6EE28770D3AE6CA125B544</idno><idno type="DOI">10.1002/ana.410120305</idno><idno type="ArticleID">ANA410120305</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Twenty‐six patients with late‐stage Parkinson disease were given 0.4 to 15 mg of pergolide mesylate daily in addition to, or as replacement for, levodopa or bromocriptine therapy. Despite treatment with individually determined optimum doses of levodopa, bromocriptine, and anticholinergics, they had shown response failure or fluctuating response. Forty percent (11 patients) were unable to tolerate pergolide. Nausea and vomiting, somnolence, and psychiatric disturbances were the most frequent side effects. Eleven of the remaining patients improved on pergolide, 2 were unchanged, and 2 were slightly worse. Among the patients who benefited, pergolide improved dose‐related response fluctuations more than non‐dose‐related fluctuations, with a reduction in number and duration of “off” periods and improvement in quality of sleep and early morning akinesia but little change in freezing episodes. Despite treatment failure in many cases, pergolide is at present the best available drug for specific latestage management problems.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>A. E. Lang MD</name><affiliations><json:string>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</json:string><json:string>Current Address: Division of Neurology, Toronto Western Hospital, 399 Bathurst St, Toronto, Ont, Canada</json:string></affiliations></json:item><json:item><name>N. Quinn MB</name><affiliations><json:string>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</json:string></affiliations></json:item><json:item><name>S. Brincat MB</name><affiliations><json:string>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</json:string></affiliations></json:item><json:item><name>C. D. Marsden MD</name><affiliations><json:string>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</json:string></affiliations></json:item><json:item><name>Dr Parkes MD</name><affiliations><json:string>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</json:string></affiliations></json:item></author><articleId><json:string>ANA410120305</json:string></articleId><language><json:string>eng</json:string></language><abstract>Twenty‐six patients with late‐stage Parkinson disease were given 0.4 to 15 mg of pergolide mesylate daily in addition to, or as replacement for, levodopa or bromocriptine therapy. Despite treatment with individually determined optimum doses of levodopa, bromocriptine, and anticholinergics, they had shown response failure or fluctuating response. Forty percent (11 patients) were unable to tolerate pergolide. Nausea and vomiting, somnolence, and psychiatric disturbances were the most frequent side effects. Eleven of the remaining patients improved on pergolide, 2 were unchanged, and 2 were slightly worse. Among the patients who benefited, pergolide improved dose‐related response fluctuations more than non‐dose‐related fluctuations, with a reduction in number and duration of “off” periods and improvement in quality of sleep and early morning akinesia but little change in freezing episodes. Despite treatment failure in many cases, pergolide is at present the best available drug for specific latestage management problems.</abstract><qualityIndicators><score>4.598</score><pdfVersion>1.3</pdfVersion><pdfPageSize>576 x 774 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1032</abstractCharCount><pdfWordCount>2870</pdfWordCount><pdfCharCount>18327</pdfCharCount><pdfPageCount>5</pdfPageCount><abstractWordCount>144</abstractWordCount></qualityIndicators><title>Pergolide in late‐stage Parkinson disease</title><genre><json:string>article</json:string></genre><host><volume>12</volume><publisherId><json:string>ANA</json:string></publisherId><pages><total>5</total><last>247</last><first>243</first></pages><issn><json:string>0364-5134</json:string></issn><issue>3</issue><subject><json:item><value>Original Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8249</json:string></eissn><title>Annals of Neurology</title><doi><json:string>10.1002/(ISSN)1531-8249</json:string></doi></host><publicationDate>1982</publicationDate><copyrightDate>1982</copyrightDate><doi><json:string>10.1002/ana.410120305</json:string></doi><id>BE242EEB7060360B7C6EE28770D3AE6CA125B544</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/BE242EEB7060360B7C6EE28770D3AE6CA125B544/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/BE242EEB7060360B7C6EE28770D3AE6CA125B544/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/BE242EEB7060360B7C6EE28770D3AE6CA125B544/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Pergolide in late‐stage Parkinson disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>1982</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Pergolide in late‐stage Parkinson disease</title><author><persName><forename type="first">A. E.</forename><surname>Lang</surname></persName><roleName type="degree">MD</roleName><note type="biography">Supported by a Research Fellowship from the Medical Research Council of Canada</note><affiliation>Supported by a Research Fellowship from the Medical Research Council of Canada</affiliation><affiliation>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</affiliation><affiliation>Current Address: Division of Neurology, Toronto Western Hospital, 399 Bathurst St, Toronto, Ont, Canada</affiliation></author><author><persName><forename type="first">N.</forename><surname>Quinn</surname></persName><roleName type="degree">MB</roleName><affiliation>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</affiliation></author><author><persName><forename type="first">S.</forename><surname>Brincat</surname></persName><roleName type="degree">MB</roleName><affiliation>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</affiliation></author><author><persName><forename type="first">C. D.</forename><surname>Marsden</surname></persName><roleName type="degree">MD</roleName><affiliation>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</affiliation></author><author><persName><surname>Parkes</surname></persName><roleName type="degree">Dr</roleName><note type="correspondence"><p>Correspondence: The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</p></note><affiliation>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</affiliation></author></analytic><monogr><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="pISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><idno type="DOI">10.1002/(ISSN)1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1982-09"></date><biblScope unit="volume">12</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="243">243</biblScope><biblScope unit="page" to="247">247</biblScope></imprint></monogr><idno type="istex">BE242EEB7060360B7C6EE28770D3AE6CA125B544</idno><idno type="DOI">10.1002/ana.410120305</idno><idno type="ArticleID">ANA410120305</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1982</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Twenty‐six patients with late‐stage Parkinson disease were given 0.4 to 15 mg of pergolide mesylate daily in addition to, or as replacement for, levodopa or bromocriptine therapy. Despite treatment with individually determined optimum doses of levodopa, bromocriptine, and anticholinergics, they had shown response failure or fluctuating response. Forty percent (11 patients) were unable to tolerate pergolide. Nausea and vomiting, somnolence, and psychiatric disturbances were the most frequent side effects. Eleven of the remaining patients improved on pergolide, 2 were unchanged, and 2 were slightly worse. Among the patients who benefited, pergolide improved dose‐related response fluctuations more than non‐dose‐related fluctuations, with a reduction in number and duration of “off” periods and improvement in quality of sleep and early morning akinesia but little change in freezing episodes. Despite treatment failure in many cases, pergolide is at present the best available drug for specific latestage management problems.</p></abstract><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Original Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1981-10-19">Received</change><change when="1982-01-17">Registration</change><change when="1982-09">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/BE242EEB7060360B7C6EE28770D3AE6CA125B544/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8249</doi><issn type="print">0364-5134</issn><issn type="electronic">1531-8249</issn><idGroup><id type="product" value="ANA"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="ANNALS OF NEUROLOGY">Annals of Neurology</title><title type="subtitle">Official Journal of the American Neurological Association and the Child Neurology Society</title><title type="short">Ann Neurol.</title></titleGroup></publicationMeta><publicationMeta level="part" position="30"><doi origin="wiley" registered="yes">10.1002/ana.v12:3</doi><numberingGroup><numbering type="journalVolume" number="12">12</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="1982-09">September 1982</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="5" status="forIssue"><doi origin="wiley" registered="yes">10.1002/ana.410120305</doi><idGroup><id type="unit" value="ANA410120305"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="articleCategory">Original Article</title><title type="tocHeading1">Original Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 1982 American Neurological Association</copyright><eventGroup><event type="manuscriptReceived" date="1981-10-19"></event><event type="manuscriptRevised" date="1982-01-15"></event><event type="manuscriptAccepted" date="1982-01-17"></event><event type="firstOnline" date="2004-10-16"></event><event type="publishedOnlineFinalForm" date="2004-10-16"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.6 mode:FullText source:HeaderRef result:HeaderRef" date="2010-05-18"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-03"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst">243</numbering><numbering type="pageLast">247</numbering></numberingGroup><correspondenceTo>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ANA.ANA410120305.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="13"></count></countGroup><titleGroup><title type="main" xml:lang="en">Pergolide in late‐stage Parkinson disease</title><title type="short" xml:lang="en">Pergolide in Parkinsonism</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" currentRef="#curr1" noteRef="#fn1"><personName><givenNames>A. E.</givenNames><familyName>Lang</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>N.</givenNames><familyName>Quinn</familyName><degrees>MB</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>S.</givenNames><familyName>Brincat</familyName><degrees>MB</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>C. D.</givenNames><familyName>Marsden</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><honorifics>Dr</honorifics><givenNames>J. D.</givenNames><familyName>Parkes</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="GB" type="organization"><unparsedAffiliation>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</unparsedAffiliation></affiliation><affiliation xml:id="curr1" countryCode="CA"><unparsedAffiliation>Division of Neurology, Toronto Western Hospital, 399 Bathurst St, Toronto, Ont, Canada</unparsedAffiliation></affiliation></affiliationGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Twenty‐six patients with late‐stage Parkinson disease were given 0.4 to 15 mg of pergolide mesylate daily in addition to, or as replacement for, levodopa or bromocriptine therapy. Despite treatment with individually determined optimum doses of levodopa, bromocriptine, and anticholinergics, they had shown response failure or fluctuating response. Forty percent (11 patients) were unable to tolerate pergolide. Nausea and vomiting, somnolence, and psychiatric disturbances were the most frequent side effects. Eleven of the remaining patients improved on pergolide, 2 were unchanged, and 2 were slightly worse. Among the patients who benefited, pergolide improved dose‐related response fluctuations more than non‐dose‐related fluctuations, with a reduction in number and duration of “off” periods and improvement in quality of sleep and early morning akinesia but little change in freezing episodes. Despite treatment failure in many cases, pergolide is at present the best available drug for specific latestage management problems.</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Supported by a Research Fellowship from the Medical Research Council of Canada</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Pergolide in late‐stage Parkinson disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Pergolide in Parkinsonism</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Pergolide in late‐stage Parkinson disease</title></titleInfo><name type="personal"><namePart type="given">A. E.</namePart><namePart type="family">Lang</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</affiliation><affiliation>Current Address: Division of Neurology, Toronto Western Hospital, 399 Bathurst St, Toronto, Ont, Canada</affiliation><description>Supported by a Research Fellowship from the Medical Research Council of Canada</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N.</namePart><namePart type="family">Quinn</namePart><namePart type="termsOfAddress">MB</namePart><affiliation>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Brincat</namePart><namePart type="termsOfAddress">MB</namePart><affiliation>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C. D.</namePart><namePart type="family">Marsden</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="termsOfAddress">Dr</namePart><namePart type="family">Parkes</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</affiliation><description>Correspondence: The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF, England</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">1982-09</dateIssued><dateCaptured encoding="w3cdtf">1981-10-19</dateCaptured><dateValid encoding="w3cdtf">1982-01-17</dateValid><copyrightDate encoding="w3cdtf">1982</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">3</extent><extent unit="references">13</extent></physicalDescription><abstract lang="en">Twenty‐six patients with late‐stage Parkinson disease were given 0.4 to 15 mg of pergolide mesylate daily in addition to, or as replacement for, levodopa or bromocriptine therapy. Despite treatment with individually determined optimum doses of levodopa, bromocriptine, and anticholinergics, they had shown response failure or fluctuating response. Forty percent (11 patients) were unable to tolerate pergolide. Nausea and vomiting, somnolence, and psychiatric disturbances were the most frequent side effects. Eleven of the remaining patients improved on pergolide, 2 were unchanged, and 2 were slightly worse. Among the patients who benefited, pergolide improved dose‐related response fluctuations more than non‐dose‐related fluctuations, with a reduction in number and duration of “off” periods and improvement in quality of sleep and early morning akinesia but little change in freezing episodes. Despite treatment failure in many cases, pergolide is at present the best available drug for specific latestage management problems.</abstract><relatedItem type="host"><titleInfo><title>Annals of Neurology</title><subTitle>Official Journal of the American Neurological Association and the Child Neurology Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Ann Neurol.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Original Article</topic></subject><identifier type="ISSN">0364-5134</identifier><identifier type="eISSN">1531-8249</identifier><identifier type="DOI">10.1002/(ISSN)1531-8249</identifier><identifier type="PublisherID">ANA</identifier><part><date>1982</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>243</start><end>247</end><total>5</total></extent></part></relatedItem><identifier type="istex">BE242EEB7060360B7C6EE28770D3AE6CA125B544</identifier><identifier type="DOI">10.1002/ana.410120305</identifier><identifier type="ArticleID">ANA410120305</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1982 American Neurological Association</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A80 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000A80 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:BE242EEB7060360B7C6EE28770D3AE6CA125B544
|texte= Pergolide in late‐stage Parkinson disease
}}
| This area was generated with Dilib version V0.6.23. |  |